Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6933-6943

  Matsueda, Satoko ^a   Takedatsu, Hiroko ^a   Yao, Akihisa ^a   Tanaka, Masahiro ^a   Noguchi, Masanori ^a   Itoh, Kyogo ^a,b   Harada, Mamoru ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIBODY; CANCER VACCINE; CD8 ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A3 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ALLELISM; ARTICLE; CANCER CELL; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HLA TYPING; HUMAN; HUMAN CELL; MALE; MULTIGENE FAMILY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING; T LYMPHOCYTE;

ALLELES; AMINO ACID MOTIFS; ANTIGENS, SURFACE; CANCER VACCINES; CELL LINE, TUMOR; COLD; EPITOPES, T-LYMPHOCYTE; GLUTAMATE CARBOXYPEPTIDASE II; HLA-A ANTIGENS; HLA-A3 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE-PHOSPHATASE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 26444620210     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0682     Document Type: Article

References (35)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
3. Correale P, Walmsley K, Nleroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300.
4. Xue BH, Zhang Y, Sosman J, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-8.
5. Correale P, Walmsley K, Zaremba S, Zhu MZ, Schlom J, Tsang KY. Generation of human cytotoxic T lymphocyte lines directed against prostate-specific (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94.
6. Horiguchi Y, Nukaya I, Okazawa K, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002; 8:3885-92.
7. Tjoa B, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-9.
8. Inoue Y, Takaue Y, Takei M, et al. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 2001;166:1508-13.
9. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36:129-38.
10. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2001; 60:5522-8.
11. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004;53:479-89.
12. + prostate cancer patients. Prostate 2004;60: 205-13.
13. Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 2003;8:193-9.
14. Sette A, Sidney J, Ninemajor HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50:201-12.
15. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1998; 160:890-7.
16. Missale G, Redeker A, Person J, et al. HLA-A31- and HLA-Aw68-restricted cvtotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993;177:751-62.
17. + cancer patients. Clin Cancer Res 2004;10: 1112-20.
18. Aizawa M. The Proceedings of the 3rd Asia-Oceania Histocompatibility Workshop Conference. Oxford: Oxford University Press; 1986. p. 1090-103.
19. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitope capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59:4056-63.
20. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002;51: 219-28.
21. Parker KC, Bednarek MA, Cokigan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
22. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and numoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
23. Ohkouchi S, Yamada A, Imai N, et al. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 2002;59:259-72.
24. + prostate cancer patients. Prostate 2003;57:152-9.
25. + prostate cancer patients. Cancer Sci 2003;94:622-7.
26. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 1990;21:1108-11.
27. Tepper SL, Jagirdar J, Heath D, Geller SA. Homology between the female paraurethral (Skene's) glands and the prostate: immunohistochemical demonstration. Arch Pathol Lab Med 1984;108:423-5.
28. Wang Y, Harada M, Yano H, et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with non-prostate adenocarcinoma. J Immunother. In press 2005.
29. Sato Y, Shomura H, Maeda Y, et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003;94:802-8.
30. Mine T, Gouhara R, Hida N, et al. Immunological evaluation of CTL precursors-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003;94: 548-56.
31. Mine T, Sato Y, Noguchi M, et al. Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004;10: 929-37.
32. Kawamoto N, Yamada A, Ohkouchi S, et al. IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients. Tissue Antigens 2003;61:352-61.
33. Rammensee HG, Friege T, Stevanovic S. MHC ligands and peptides motifs. Immunogenetics 1995; 41:178-228.
34. Sidney J, Grey HM, Southwood S, et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996;45: 79-93.
35. Bettinotti MP, Kim CJ, Lee KH, et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998;161:877-89.